VivoSeq
Neurology

Postherpetic Neuralgia

56

Pipeline Programs↗

8

Active Trials↗

36

Companies Involved↗

Postherpetic Neuralgia is a moderately active landscape with 56 programs across 36 companies. The most active players are Pfizer, Merck & Co., Averitas Pharma, Inc.. 14 therapies are approved with 11 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

61/100

Pipeline Velocity

6/100

Mech. Concentration

15/100

Completion Rate

84/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

3 programs

Phase 2Merck & Co. logo

Merck & Co.

3 programs

Phase 2A

Averitas Pharma, Inc.

2 programs

Phase 2AbbVie logo

AbbVie

1 program

Phase 2S

Shanghai SIMR Biotechnology Co., Ltd.

1 program

Phase 2Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

99%

Small molecule

68 of 69 classified programs — the dominant modality here.

1%ALL OTHERSMonoclonal antibody11%

Small molecule leads; the ring shows all 69 classified programs, each share of the total. Modality classified for 100% of 70 pipeline programs.

Analysis

Trial Status

67

clinical trials

Completed47 · 70%
Terminated9 · 13%
Not yet recruiting5 · 7%
Unknown status3 · 4%
Recruiting2 · 3%
Active, not recruiting1 · 1%

Clinical Trials

Trial Activity

67 trials

Esketamine Combined Pregabalin and Duloxetine for Postherpetic Neuralgia
Recruiting·—·N/A·NCT06896994·150 enrolled
The Treatment of Postherpetic Neuralgia in the Head and Face With Superficial Needling Combined With Electroacupuncture
Recruiting·ZZhejiang Chinese Medical University·N/A·NCT06420778·124 enrolled
A Study of ONO-1110 in Patients With Postherpetic Neuralgia
Active, not recruiting·Ono Pharmaceutical Co. Ltd logoOno Pharmaceutical Co. Ltd·Phase 2·NCT06708416·140 enrolled
Y-4 to Treat the Postherpetic Neuralgia
Not yet recruiting·NNeurodawn Pharmaceutical Co., Ltd.·Phase 2·NCT07275762·160 enrolled
Effectiveness of Warm Acupuncture in Patients with Postherpetic Neuralgia
Not yet recruiting·UUniversity of Medicine and Pharmacy at Ho Chi Minh City·N/A·NCT06893172·36 enrolled
Ketamine for Postherpetic Neuralgia With Depression
Not yet recruiting·HHuazhong University of Science and Technology·Phase 4·NCT06968624·50 enrolled
Esketamine Combined With PRF for Trigeminal Postherpetic Neuralgia
Not yet recruiting·—·N/A·NCT06914180·174 enrolled
Esketamine Combined With PRF of DRG for Postherpetic Neuralgia
Not yet recruiting·—·N/A·NCT06914193·186 enrolled
Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia
Completed·LLexicon Pharmaceuticals·Phase 2·NCT04662281·79 enrolled
To Evaluate the Efficacy and Safety of SR419 in Patients With Postherpetic Neuralgia (PHN)
Completed·SShanghai SIMR Biotechnology Co., Ltd.·Phase 2·NCT05357677·83 enrolled
To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Postherpetic Neuralgia
Completed·Haisco Pharmaceutical Group Co., Ltd. logoHaisco Pharmaceutical Group Co., Ltd.·Phase 3·NCT05140863·372 enrolled
A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN)
Completed·KKalypsys, Inc.·Phase 2·NCT00576108·48 enrolled
Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)
Completed·PPurdue Pharma LP·Phase 2·NCT01688947·105 enrolled
An Open-Label Follow-on Trial to Assess the Long-Term Safety and Efficacy of Oral SPM 927 in Subjects With Postherpetic Neuralgia (PHN)
Completed·UCB logoUCB·Phase 2·NCT00238511
Phase III Randomized Controlled Study of Morphine and Nortriptyline in the Management of Postherpetic Neuralgia
Completed·NNational Center for Research Resources (NCRR)·Phase 3·NCT00004390·120 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)